This is an open label trial of a supplement called HMB in patients with ALS. The researchers are evaluating its safety and tolerability, as well as its ability to lower insulin-like growth-factor binding protein 7 (IGFBP7) and Neurofilament light chain levels (NFL) and to slow ALS Functional Rating Scale, Revised (ALSFRS-R) progression.
Male or female aged at least 18 years.
Sporadic or familial ALS diagnosed as per Gold Coast Criteria (37).
Patient is able to understand and express informed consent (in the opinion of the site investigator).
Patient is able to read and write English.
Actively or recently (within past 30 days) participating in another intervention trial.
Currently or recently (within 30 days) taking HMB
Prior side effects from HMB deemed to be significant by the investigator
Patient has a medical or psychiatric illness that could in the investigator's opinion interfere with the patient's ability to participate in this study.
Duke University
Lead sponsor
Temple University
Collaborator